Archives: ClinicianPOV

Switching Disease Modifying Therapies in MS Due to Breakthrough Disease Activity, Inadequate Response to Therapy

Disease-modifying therapies can reduce multiple sclerosis relapse rates. Jonathan E. Howard, MD, a neurologist and associate professor of neurology and psychiatry at
NYU Grossman School of Medicine provides insight on factors that contribute to switching disease modifying therapies in MS due to breakthrough disease activity or inadequate response to therapy.

Treating Tardive Dyskinesia With VMAT2 Agents

Christoph U. Correll, MD, professor of psychiatry and molecular medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital, discusses how 2 new VMAT2 agents are changing the management of tardive dyskinesia.

Fatigue in Multiple Sclerosis: A Common and Debilitating Symptom

Fatigue is one of the most frequently reported symptoms in people with MS; however, its etiology and presentation can vary from patient to patient. In this interview, approaches to identifying fatigue and a team-based strategy for minimizing its impact on patients’ lives are discussed.

Next clinicianpov in Clinician POV